Study S000523

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Not Receiving Positive Airway Pressure (PAP) Therapy

ClinicalTrials.gov record

Registration

Registration: NCT06974851
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: QUADRUPLE
Status: RECRUITING
Enrollment: 140
Start: 2025-07-25
Primary completion: 2026-12
Lead sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
Conditions: Bstructive Sleep Apnea (OSA) and Obesity
Interventions: DRUG:HRS9531; DRUG:HRS9531placebo
Results posted: FALSE
Individual participant data sharing: UNDECIDED

Registered primary outcomes

Percentage Change in AHI from Baseline at Week 52 of Treatment [52week]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.